瑞戈非尼联合哌立福辛诱导人肝癌HepG2细胞凋亡的分子机制研究

doi:10.11904/j.issn.1002-3070.2021.05.004

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (5): 408-413.doi: 10.11904/j.issn.1002-3070.2021.05.004

瑞戈非尼联合哌立福辛诱导人肝癌HepG2细胞凋亡的分子机制研究

陈雪健, 王伟, 周健, 李宁, 张浩鹏, 徐力善

哈尔滨医科大学附属第四医院肿瘤外科肝胆外科(哈尔滨 150001)

收稿日期:2020-12-28 修回日期:2021-02-04 发布日期:2021-10-25
通讯作者: 徐力善,E-mail:Xulishan001@hotmail.com
作者简介:陈雪健,男,(1994-),硕士研究生,从事消化系统肿瘤方面的研究。
基金资助:
哈尔滨医科大学附属第四医院火炬计划(编号:HYDSYHJ201903)

Research on the molecular mechanism of regorafenib combined with perifosine in inducing apoptosis of human hepatoma HepG2 cells

CHEN Xuejian, WANG Wei, ZHOU Jian, LI Ning, ZHANG Haopeng, XU Lishan

Department of Oncological and Hepatobiliary Surgery,The Fourth Affiliated Hospital of Harbin Medical University,Harbin 150001,China

Received:2020-12-28 Revised:2021-02-04 Published:2021-10-25

摘要/Abstract

摘要： 目的探讨瑞戈非尼联合哌立福辛(AKT抑制剂)对人肝癌HepG2细胞凋亡的分子机制。方法不同浓度瑞戈非尼(1、5、10、15、20、25 μmol/L)处理肝癌细胞后,通过CCK-8检测其细胞存活率;再设置不同浓度瑞戈非尼(0、5、10、20 μmol/L)处理肝癌细胞后,流式细胞仪检测细胞凋亡;用免疫印迹法(Western blot)检测Bax、Bcl-2、p-AKT、AKT、p21、p27、Cleaved-caspase-8、Cleaved-caspase-9的表达情况;设置哌立福辛组(10 μmol/L)、瑞戈非尼组(20 μmol/L)及双药联合组(哌立福辛10 μmol/L联合瑞戈非尼20 μmol/L),检测细胞凋亡及相关蛋白表达变化。结果从5 μmol/L浓度起,瑞戈非尼可剂量依赖性的抑制肝癌细胞增殖(P＜0.05);Bcl-2及p-AKT表达下调,Bax、p21、p27、Cleaved-caspase-8、Cleaved-caspase-9表达上调(P＜0.05);瑞戈非尼和哌立福辛双药联合应用后,细胞凋亡率、Bax表达量明显增加(P＜0.05),Bcl-2、p-AKT表达量下降程度均较单独应用哌立福辛及瑞戈非尼明显(P＜0.05)。结论瑞戈非尼通过增加p21、p27、Bax、caspase-8、caspase-9的表达,减少Bcl-2、p-AKT的表达,来诱导肝癌细胞凋亡,并且瑞戈非尼与哌立福辛双药联合应用后,明显增加肝癌细胞凋亡率,为药物治疗肝癌提供新的理论基础和思路。

关键词: 瑞戈非尼, AKT抑制剂, 肝癌, 细胞凋亡

Abstract: Objective The Objective of this study was to investigate the molecular mechanism of regorafenib combined with perifoxin(AKT inhibitor)in apoptosis induction of human hepatoma HepG2 cells. Methods After treated with different concentrations of regorafenib(1,5,10,15,20 and 25 μmol/L),the cell survival rate was detected in hepatoma cells by CCK-8 assay;and then different concentrations of regorafenib(0,5,10 and 20 μmol/L)were setup.Flow cytometry was used to detect apoptosis.The expression of Bax,Bcl-2,P-AKT,AKT,p21,p27,Cleaved-caspase-8 and Cleaved-caspase-9 was detected by Western blot.Perifosine group(10 μmol/L),regorafenib group(20 μmol/L)and the drug combination group(perifosine 10 μmol/L combined with regorafenib 20 μmol/L)were set to detect cell apoptosis and related protein expression changes. Results Regorafenib inhibited proliferation of hepatoma cells in a dose-dependent manner from the concentration of 5 μmol/L(P＜0.05).The expression of Bcl-2 and P-AKT was down-regulated and the expression of Bax,p21,p27,Cleaved-caspase-8 and Cleaved-caspase-9 was up-regulated(P＜0.05).After the combined application of regorafenib and perifosine,the apoptosis rate and Bax expression were significantly increased(P＜0.05),and the decrease of Bcl-2 and P-AKT expression was more obvious than that of perifosine or regorafenib alone(P＜0.05). Conclusion Regorafenib can induce apoptosis in hepatma cells by increasing the expression of p21,p27,Bax,Caspase-8 and Caspase-9,and reducing the expression of Bcl-2 and P-AKT.The combined application of regorafenib and perifosine significantly increases the apoptosis rate of hepatma cells,providing a new theoretical basis and ideas for the drug treatment of liver cancer.

Key words: Regorafenib, AKT inhibitor, Hepatoma carcinoma, Apoptosis

中图分类号:

R735.7

陈雪健, 王伟, 周健, 李宁, 张浩鹏, 徐力善. 瑞戈非尼联合哌立福辛诱导人肝癌HepG2细胞凋亡的分子机制研究[J]. 实用肿瘤学杂志, 2021, 35(5): 408-413.

CHEN Xuejian, WANG Wei, ZHOU Jian, LI Ning, ZHANG Haopeng, XU Lishan. Research on the molecular mechanism of regorafenib combined with perifosine in inducing apoptosis of human hepatoma HepG2 cells[J]. Journal of Practical Oncology, 2021, 35(5): 408-413.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.05.004

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I5/408

参考文献

1 Ettrich TJ,Seufferlein T.Regorafenib[J].Recent Results Cancer Res,2018,211:45-56.
2 Juengpanich S,Topatana W,Lu C,et al.Role of cellular,molecular and tumor microenvironment in hepatocellular carcinoma:possible targets and future directions in the regorafenib era[J].Int J Cancer,2020,147(7):1778-1792.
3 Forner A,Reig M,Bruix J.Hepatocellular carcinoma[J].Lancet,2018,391(10127):1301-1314.
4 Fernández-Barrena MG,Arechederra M,Colyn L,et al.Epigenetics in hepatocellular carcinoma development and therapy:the tip of the iceberg[J].JHEP Rep,2020,2(6):100167.
5 Personeni N,Pressiani T,Santoro A,et al.Regorafenib in hepatocellular carcinoma:latest evidence and clinical implications[J].Drugs Context,2018,7:212533.
6 Personeni N,Pressiani T,Bozzarelli S,et al.Targeted agents for second-line treatment of advanced hepatocellular carcinoma[J].World J Gastrointest Oncol,2019,11(10):788-803.
7 Keating GM.Sorafenib:a review in hepatocellular carcinoma[J].Target Oncol,2017,12(2):243-253.
8 Bangaru S,Marrero JA,Singal AG.Review article:new therapeutic interventions for advanced hepatocellular carcinoma[J].Aliment Pharmacol Ther,2020,51(1):78-89.
9 Kreis NN,Louwen F,Yuan J.Less understood issues:p21(Cip1)in mitosis and its therapeutic potential[J].Oncogene,2015,34(14):1758-1767.
10 Kreis NN,Louwen F,Yuan J.The multifaceted p21(Cip1/Waf1/CDKN1A)in cell differentiation,migration and cancer therapy[J].Cancers(Basel),2019,11(9):1220.
11 Abbastabar M,Kheyrollah M,Azizian K,et al.Multiple functions of p27 in cell cycle,apoptosis,epigenetic modification and transcriptional regulation for the control of cell growth:a double-edged sword protein[J].DNA Repair(Amst),2018,69:63-72.
12 Tang F,Wang Y,Hemmings BA,et al.PKB/Akt-dependent regulation of inflammation in cancer[J].Semin Cancer Biol,2018,48:62-69.
13 Manning BD,Toker A.AKT/PKB signaling:navigating the network[J].Cell,2017,169(3):381-405.
14 Campbell KJ,Tait SWG.Targeting BCL-2 regulated apoptosis in cancer[J].Open Biol,2018,8(5):180002.
15 Raghav PK,Kumar R,Kumar V,et al.Docking-based approach for identification of mutations that disrupt binding between Bcl-2 and Bax proteins:inducing apoptosis in cancer cells[J].Mol Genet Genomic Med,2019,7(11):e910.
16 Zacarías-Lara OJ,Correa-Basurto J,Bello M.Exploring the conformational and binding properties of unphosphorylated/phosphorylated monomeric and trimeric Bcl-2 through docking and molecular dynamics simulations[J].Biopolymers,2016,105(7):393-413.
17 Liu Z,Ding Y,Ye N,et al.Direct activation of Bax protein for cancer therapy[J].Med Res Rev,2016,36(2):313-341.
18 Shalini S,Dorstyn L,Dawar S,et al.Old,new and emerging functions of caspases[J].Cell Death Differ,2015,22(4):526-539.
19 Mandal R,Barrón JC,Kostova I,et al.Caspase-8:The double-edged sword[J].Biochim Biophys Acta Rev Cancer,2020,1873(2):188357.
20 Ramirez MLG,Salvesen GS.A primer on caspase mechanisms[J].Semin Cell Dev Biol,2018,82:79-85.

[1]	金升烨, 庞达. 溶瘤病毒诱导肿瘤凋亡及激活抗肿瘤免疫机制的研究进展[J]. 实用肿瘤学杂志, 2021, 35(5): 462-467.
[2]	朱云芳, 陈杨, 朱林芳, 石青萍, 成会荣, 任思颖, 文洪梅. 2016年云南省肿瘤登记地区肝癌发病和死亡情况及2011—2016年变化趋势[J]. 实用肿瘤学杂志, 2021, 35(2): 97-102.
[3]	胡启辉, 杜毅超, 贺凯, 付文广, 夏先明. 内质网应激在肝癌中的作用[J]. 实用肿瘤学杂志, 2021, 35(2): 160-164.
[4]	白明宇, 陈丽莉. 2015—2019年营口市城市居民肝癌死因分析[J]. 实用肿瘤学杂志, 2020, 34(6): 500-503.
[5]	石琳娜, 隋红. 原发性肝癌免疫检查点抑制剂治疗的进展与挑战[J]. 实用肿瘤学杂志, 2020, 34(6): 560-564.
[6]	赵仁成, 林子棠, 余卫军, 雷林, 刘峥, 徐英, 郭艳芳, 彭绩. 2017—2019年深圳市宝安区40~74岁常住居民五癌风险流行状况分析[J]. 实用肿瘤学杂志, 2020, 34(4): 315-320.
[7]	庞晨, 张秀玲, 张锡流. 铁皮石斛抑制上皮源性恶性肿瘤的研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 362-367.
[8]	周健, 陈雪健, 王伟, 李宁, 孙振宇, 徐力善. 沉默PRMT5基因对人肝癌细胞生物学行为的影响[J]. 实用肿瘤学杂志, 2020, 34(3): 208-213.
[9]	王飞, 朱贲贲. 丙泊酚经HIF-1α信号通路对头颈鳞状细胞癌SCC-74细胞增殖、凋亡与侵袭的影响[J]. 实用肿瘤学杂志, 2020, 34(2): 120-125.
[10]	张从义, 崔逸峰, 李宝宝, 刘连新. 细胞分裂周期7蛋白在肝癌组织的表达及其对肝癌细胞增殖和侵袭的影响[J]. 实用肿瘤学杂志, 2020, 34(2): 150-155.
[11]	黄梨, 龙佑梅, 付义霞, 夏良斌. 紫檀芪对卵巢癌SKOV3细胞凋亡和糖酵解的影响及机制研究[J]. 实用肿瘤学杂志, 2019, 33(6): 502-507.
[12]	陈子印, 白艳春, 曹洋森, 李坚, 徐丽丽, 赵秋爽, 汪洋. 呼吸门控技术在肝癌大分割放射治疗方面的剂量学优势[J]. 实用肿瘤学杂志, 2019, 33(6): 536-539.
[13]	李素素, 周春祥. NKT细胞对肝癌免疫应答的双向调控作用[J]. 实用肿瘤学杂志, 2019, 33(6): 540-543.
[14]	安巍巍, 唐雅莉, 赵莲花, 杨悦, 王新玲. 红松松塔提取物多聚苯丙素-多糖复合物诱导人乳腺癌MCF-7细胞凋亡[J]. 实用肿瘤学杂志, 2019, 33(4): 289-293.
[15]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.

瑞戈非尼联合哌立福辛诱导人肝癌HepG2细胞凋亡的分子机制研究

Research on the molecular mechanism of regorafenib combined with perifosine in inducing apoptosis of human hepatoma HepG2 cells

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价